Aratana Therapeutics, Inc. (PETX) Expected to Announce Quarterly Sales of $4.60 Million

Analysts expect that Aratana Therapeutics, Inc. (NASDAQ:PETX) will post $4.60 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aratana Therapeutics’ earnings, with the lowest sales estimate coming in at $4.50 million and the highest estimate coming in at $4.70 million. Aratana Therapeutics posted sales of $38.05 million in the same quarter last year, which suggests a negative year-over-year growth rate of 87.9%. The business is scheduled to issue its next earnings report after the market closes on Thursday, August 3rd.

On average, analysts expect that Aratana Therapeutics will report full-year sales of $4.60 million for the current financial year, with estimates ranging from $19.30 million to $28.80 million. For the next financial year, analysts forecast that the company will report sales of $58.81 million per share, with estimates ranging from $38.50 million to $82.42 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $3.05 million. Aratana Therapeutics had a negative return on equity of 14.95% and a negative net margin of 66.72%. The business’s revenue for the quarter was up 2135.3% on a year-over-year basis. During the same period last year, the company earned ($0.52) earnings per share.

A number of equities analysts recently weighed in on the stock. BidaskClub lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Jefferies Group LLC restated a “buy” rating and set a $8.00 price target on shares of Aratana Therapeutics in a research report on Sunday, May 14th. Finally, Stifel Nicolaus lowered their price target on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $10.00.

A number of institutional investors have recently bought and sold shares of the stock. Janney Montgomery Scott LLC raised its position in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,200 shares during the last quarter. American International Group Inc. raised its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the last quarter. Geneva Advisors LLC raised its position in Aratana Therapeutics by 4.1% in the first quarter. Geneva Advisors LLC now owns 77,288 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,044 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC raised its position in Aratana Therapeutics by 8.3% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 67.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Aratana Therapeutics, Inc. (PETX) Expected to Announce Quarterly Sales of $4.60 Million” was posted by Rincon Hill News and is the sole property of of Rincon Hill News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://rinconhillneighbors.org/2017/08/19/aratana-therapeutics-inc-petx-expected-to-announce-quarterly-sales-of-4-60-million-updated-updated.html.

Aratana Therapeutics (PETX) traded down 0.89% during midday trading on Friday, reaching $6.69. The company had a trading volume of 278,611 shares. The firm has a 50-day moving average price of $7.05 and a 200-day moving average price of $6.47. The company’s market capitalization is $281.45 million. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.